EHA Unplugged

In this episode Prof. Frank Leebeek reflects on his career in hematology, highlighting a lifelong commitment to bridging clinical practice and research. 

From his early interest in fibrinolysis during medical school to his current role as Chair of the Department of Hematology at Erasmus Medical Center and Board member at EHA, Prof. Leebeek shares how a dual commitment to research and patient care has shaped his path. 

The conversation explores key milestones in bleeding disorders research, including large-scale studies on von Willebrand disease that helped improve awareness, diagnosis, and patient-reported outcomes. Prof. Leebeek also discusses his involvement in pioneering gene therapy trials for hemophilia, which have transformed treatment paradigms and patients’ quality of life, while noting ongoing challenges in access and affordability. Beyond research, he reflects on the importance of collaboration, the value of long-term patient relationships, and the role of European-level initiatives in advancing hematology care. 

Tune in to hear insights from a leading figure in benign hematology and learn how sustained collaboration and innovation continue to drive progress in the field. 

Guest: Prof Frank Leebeek 
Affiliation: Erasmus Medical Center, Rotterdam, The Netherlands    
Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA  

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.
⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠
Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠
LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠

What does it take to design and lead a clinical trial in hematology? In this episode of EHA Unplugged, Prof. Elias K. Mai shares his experience transitioning from clinical practice to becoming a principal investigator, and how the EHA Clinical Research Training in Hematology (CRTH) program helped shape his path. 

Prof. Mai reflects on the practical and often underappreciated challenges of clinical trial design—from budgeting and statistical planning to ethical considerations and regulatory requirements. He highlights the importance of mentorship and peer networks, as well as the need for persistence when ideas are ahead of their time. The conversation also explores the skills hematologists need to get started in clinical research, with a clear message: developing trials is a multifaceted process that requires both scientific expertise and hands-on learning. 

Whether you are early in your career or considering a move into clinical research, this episode offers valuable insights into how to take the first steps, overcome challenges, and ultimately contribute to improving patient care through clinical trials.

Guests: 
Prof Elias K. Mai
Heidelberg University Hospital, Heidelberg, Germany

Host: Isabel Olivera Martinez, PhD

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.
⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠
Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠
LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma. 

The conversation explores how recent therapeutic advances—including 14 newly approved treatment regimens, CAR T-cell therapies, bispecific antibodies and antibody-drug conjugates—have reshaped the treatment landscape and informed the latest recommendations. The experts discuss the integration of novel prognostic tools such as minimal residual disease (MRD), circulating tumour cells and mass spectrometry, and their evolving role in risk stratification. 

The episode also reviews key recommendations for frontline management and provides practical guidance for selecting therapies in relapsed and refractory multiple myeloma. Throughout the discussion, the speakers highlight how the updated guidelines support clinicians in navigating an increasingly complex therapeutic landscape. 

Guests: 
Prof. Meletios Dimopoulos and Prof. Evangelos Terpos  
National and Kapodistrian University of Athens, Greece

Host: Prof. Pieter Sonneveld
Erasmus University Medical Center, Rotterdam, The Netherlands 

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.
⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠
Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠
LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. 

In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while  managing toxicity. The episode highlights the potential for these therapies to replace transplants by inducing deep, durable responses. Dr. Otero also explores new targets like GPRC5D, offering insights into future treatment possibilities.

Guests: 
Dr Paula Rodríguez-Otero 
Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain  

Host: Isabel Olivera Martinez, PhD

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.
⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠
Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠
LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML, with two agents already receiving FDA breakthrough therapy designation. 

In this episode, Dr Scott Armstrong and Prof Marc Raaijmakers explore the scientific rationale behind menin inhibition, identify which AML patient populations are most likely to benefit, and review the current clinical evidence supporting their use in defined molecular subtypes.
Guests: 
Dr Scott Armstrong 
Dana-Farber Cancer Institute 
Prof Marc Raaijmakers 
Erasmus Medical Center

Host: Isabel Olivera Martinez, PhD

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.
⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠
Facebook: ⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠
LinkedIn: ⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠